FTC Solar (NASDAQ:FTCI) reported quarterly adjusted losses of $(0.11) per share which met the analyst consensus estimate. This is a 35.29 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $26.20 million which missed the analyst consensus estimate of $30.38 million by 13.76 percent. This is a 74.24 percent decrease over sales of $101.72 million the same period last year.
Phase 3 Studies Of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope For Patients With Multidrug-Resistant Infections And Limited Treatment Options
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Pfizer Inc.
